A Multicenter Cohort Study on the Adverse Effects Evaluation After Messenger RNA COVID-19 Vaccination Among Pregnant Healthcare Employees in Penang General Hospitals

Abstract

IntroductionThe year 2020 saw the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which became a great threat to public health worldwide. The exponential spread of the disease with millions of lives lost worldwide saw the emergence of an accelerated vaccine development with emergency approval from well-known regulatory bodies such as the US Food and Drug Administration, followed by widespread vaccine deployment despite a paucity in safety profile data. This issue becomes even more pronounced when it involves expectant mothers considering the possible undesirable effect toward the unborn child.MethodThis was a retrospective cohort study which was conducted at six general hospitals in the state of Penang, Malaysia. All the pregnant employees who have consented to take the mRNA COVID-19 vaccine and participate in this study were monitored from the time of their first vaccination and up to 28 days after they delivered their babies.ResultsAll the participants had adequate maximum vertical pocket (MVP) and no obvious anomalies or detection of intrauterine growth restriction (IUGR) were detected during the second trimester. However, one subject was reported to have miscarried during the second trimester. The reported mean neonate birth weight was 3.0 kg with the mean Apgar score of 8.8 and 9.8 at 1 and 5 min, respectively. Approximately seven (5.8%) neonates were reported to be small for their gestational age. Another three (2.5%) neonates were reported to have anomalies.ConclusionAs a whole, the inference that can be made from this study is that mRNA COVID-19 vaccine appears to be safe in pregnant women regardless of the trimester as the findings did not show obvious safety warning signs.

Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis

“…We included 16 studies (425 867 women) reporting SARS-CoV-2 infection-related outcomes6 7 17 19 21 31 33 36 38–45 and 35 (1 362 172 women) reporting pregnancy-related maternal and offspring outcomes in the secondary analysis 17 18 21–24 29–34 36 38 39 41–60. Twenty-three studies reported reactogenicity outcomes (94 206 women) following vaccination 38 39 46 61–80…”

Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis

“…[157] We included 134 studies (87% RNA vaccines) published until December 31, 2022. We found more than 20 new studies that our present review evaluating the safety of COVID-19 vaccines during pregnancy [158] , [159] , [160] , [161] , [162] , [163] , [164] , [165] , [166] , [167] , [168] , [169] , [170] , [171] , [172] , [173] , [174] , [175] , [176] , [88] , [177] . Most of studies were conducted in Europe [159] , [160] , [162] , [169] , [170] , [171] , [177] , North America [163] , [168] , [172] , [173] , [175] , [88] and Asia [158] , [161] , [164] , [167] , [174] , [176] .…”

Knowledge, acceptance and concerns regarding COVID-19 vaccination among pregnant women on the east coast of Peninsular Malaysia: Across-sectional study

“…While safety concerns exist for COVID-19 vaccines due to their new technology and the initial exclusion of pregnant women from efficacy trials, emerging data offer reassuring insights into their safety. 13 , 14 …”